Gujarat Themis Biosyn Ltd vs Onyx Biotec Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 364.85 as of 12 May 14:06 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 9.8 on March 2021 to 62.8 on March 2025 . This represents a CAGR of 44.99% over 5 yearsThe P/E Ratio of Onyx Biotec Ltd changed from 21.3 on March 2025 to 21.3 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 295.88 crore on March 2021 to ₹ 3067 crore on March 2025 . This represents a CAGR of 59.64% over 5 yearsThe Market Cap of Onyx Biotec Ltd changed from ₹ 105.17 crore on March 2025 to ₹ 105.17 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 43.78 crore as compare to the Sep '25 revenue of ₹ 43.17 crore. This represent the growth of 1.41% The revenue of Onyx Biotec Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 21.72 crore as compare to the Sep '25 ebitda of ₹ 21.76 crore. This represent the decline of -0.18% The ebitda of Onyx Biotec Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 13.24 crore to ₹ 12.46 crore over 7 quarters. This represents a CAGR of -3.41% The net profit of Onyx Biotec Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Onyx Biotec Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Onyx Biotec Ltd

Onyx Biotec Limited was incorporated as Onyx Biotec Private Limited', pursuant to a Certificate of Incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. & Chandigarh.
Further, Company converted into a Public Limited and the name was changed to Onyx Biotec Limited' and a fresh Certificate of Incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre. Onyx started its operation in pharmaceutical industry with sterile water for injections with capacity of 2 lacs units per day in year 2010.
Since then, Onyx is engaged in Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc. to major corporations, which includes the top pharma companies. Presently, the Company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Onyx Biotec Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Onyx Biotec Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,213 Cr while Market cap of Onyx Biotec Ltd is 65 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Onyx Biotec Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Onyx Biotec Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Onyx Biotec Ltd?

As of May 12, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹386.65. On the other hand, Onyx Biotec Ltd stock price is INR ₹35.95.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Onyx Biotec Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Onyx Biotec Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.